» Articles » PMID: 22741037

High-throughput Molecular Analysis from Leftover of Fine Needle Aspiration Cytology of Mammographically Detected Breast Cancer

Abstract

We investigated whether residual material from diagnostic smears of fine needle aspirations (FNAs) of mammographically detected breast lesions can be successfully used to extract RNA for reliable gene expression analysis. Twenty-eight patients underwent FNA of breast lesions under ultrasonographic guidance. After smearing slides for cytology, residual cells were rinsed with TRIzol to recover RNA. RNA yield ranged from 0.78 to 88.40 µg per sample. FNA leftovers from 23 nonpalpable breast cancers were selected for gene expression profiling using oligonucleotide microarrays. Clusters generated by global expression profiles partitioned samples in well-distinguished subgroups that overlapped with clusters obtained using "biologic scores" (cytohistologic variables) and differed from clusters based on "technical scores" (RNA/complementary RNA/microarray quality). Microarray profiling used to measure the grade of differentiation and estrogen receptor and ERBB2/HER2 status reflected the results obtained by histology and immunohistochemistry. Given that proliferative status in the FNA material is not always assessable, we designed and performed on FNA leftover a multiprobe genomic signature for proliferation genes that strongly correlated with the Ki67 index examined on histologic material. These findings show that cells residual to cytologic smears of FNA are suitable for obtaining high-quality RNA for high-throughput analysis even when taken from small nonpalpable breast lesions.

Citing Articles

Suitability of ultrasound-guided fine-needle aspiration biopsy for transcriptome sequencing of the canine prostate.

Thiemeyer H, Taher L, Schille J, Harder L, Hungerbuehler S, Mischke R Sci Rep. 2019; 9(1):13216.

PMID: 31519932 PMC: 6744464. DOI: 10.1038/s41598-019-49271-1.


A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions.

Franzen B, Kamali-Moghaddam M, Alexeyenko A, Hatschek T, Becker S, Wik L Mol Oncol. 2018; 12(9):1415-1428.

PMID: 30019538 PMC: 6120227. DOI: 10.1002/1878-0261.12350.


Search for neuro-endocrine markers (chromogranin A, synaptophysin and VGF) in breast cancers. An integrated approach using immunohistochemistry and gene expression profiling.

Annaratone L, Medico E, Rangel N, Castellano I, Marchio C, Sapino A Endocr Pathol. 2013; 25(3):219-28.

PMID: 24277232 PMC: 4160574. DOI: 10.1007/s12022-013-9277-4.

References
1.
Bussolati G, Annaratone L, Medico E, DArmento G, Sapino A . Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS One. 2011; 6(6):e21043. PMC: 3115967. DOI: 10.1371/journal.pone.0021043. View

2.
Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L . European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann Oncol. 2007; 19(4):614-22. DOI: 10.1093/annonc/mdm481. View

3.
Assersohn L, Gangi L, Zhao Y, Dowsett M, Simon R, Powles T . The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res. 2002; 8(3):794-801. View

4.
Sotiriou C, Khanna C, Jazaeri A, Petersen D, Liu E . Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn. 2002; 4(1):30-6. PMC: 1906976. DOI: 10.1016/S1525-1578(10)60677-0. View

5.
Sotiriou C, Powles T, Dowsett M, Jazaeri A, Feldman A, Assersohn L . Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4(3):R3. PMC: 111028. DOI: 10.1186/bcr433. View